CN119233828A - 纳米胶囊化药物组合物及其用途 - Google Patents

纳米胶囊化药物组合物及其用途 Download PDF

Info

Publication number
CN119233828A
CN119233828A CN202380040313.7A CN202380040313A CN119233828A CN 119233828 A CN119233828 A CN 119233828A CN 202380040313 A CN202380040313 A CN 202380040313A CN 119233828 A CN119233828 A CN 119233828A
Authority
CN
China
Prior art keywords
poly
polymer
combination
pharmaceutical composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380040313.7A
Other languages
English (en)
Chinese (zh)
Inventor
陆路
尹锐
姜世勃
刘泽众
谢明
周洁
王欣玲
王茜
徐巍
潘京
张羽蓓
齐凯
孙群
王林
邹志英
陶春林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Fujun Gene Co
ANP Technologies Inc
Original Assignee
Fudan University
Fujun Gene Co
ANP Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University, Fujun Gene Co, ANP Technologies Inc filed Critical Fudan University
Publication of CN119233828A publication Critical patent/CN119233828A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380040313.7A 2022-03-14 2023-03-13 纳米胶囊化药物组合物及其用途 Pending CN119233828A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263319585P 2022-03-14 2022-03-14
US63/319,585 2022-03-14
US202263335408P 2022-04-27 2022-04-27
US63/335,408 2022-04-27
US202263382149P 2022-11-03 2022-11-03
US63/382,149 2022-11-03
PCT/US2023/064235 WO2023178038A1 (en) 2022-03-14 2023-03-13 Nanoencapsulated pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
CN119233828A true CN119233828A (zh) 2024-12-31

Family

ID=88024214

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380040313.7A Pending CN119233828A (zh) 2022-03-14 2023-03-13 纳米胶囊化药物组合物及其用途
CN202380040311.8A Pending CN119212725A (zh) 2022-03-14 2023-03-13 聚合物纳米聚集体药物组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380040311.8A Pending CN119212725A (zh) 2022-03-14 2023-03-13 聚合物纳米聚集体药物组合物及其用途

Country Status (5)

Country Link
US (2) US20250195443A1 (https=)
EP (1) EP4493219A1 (https=)
JP (1) JP2025509728A (https=)
CN (2) CN119233828A (https=)
WO (2) WO2023178038A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121319127A (zh) * 2025-12-04 2026-01-13 广州国家实验室 铁蛋白突变体及其用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024186626A1 (en) * 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
CN117919425B (zh) * 2024-03-14 2024-06-14 深圳国家感染性疾病临床医学研究中心 mTOR抑制剂在制备抑制猴痘病毒的制剂中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1623437B1 (en) * 2003-04-24 2007-12-05 Carbon Nanotechnologies, Inc. Conductive carbon nanotube-polymer composite
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
EP2661281B1 (en) * 2011-01-09 2021-03-10 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
KR20140041522A (ko) * 2011-05-09 2014-04-04 인스티튜트 퀴믹 데 사리아 약물 전달용 중합체 나노입자
FR2975090B1 (fr) * 2011-05-11 2017-12-15 Commissariat Energie Atomique Nanoparticules autodispersantes
WO2013020005A2 (en) * 2011-08-03 2013-02-07 Anp Technologies, Inc. Oxazoline polymer compositions and use thereof
US20190015350A1 (en) * 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
EP2953648B1 (en) * 2013-02-05 2021-04-21 ANP Technologies, Inc. Nanoparticles containing a taxane and their use
JP2019151510A (ja) * 2018-03-01 2019-09-12 日立造船株式会社 カーボンナノチューブ複合体の製造方法および多孔質金属材料の製造方法
US11213482B1 (en) * 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
WO2022174171A1 (en) * 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121319127A (zh) * 2025-12-04 2026-01-13 广州国家实验室 铁蛋白突变体及其用途

Also Published As

Publication number Publication date
WO2023177629A1 (en) 2023-09-21
US20250195443A1 (en) 2025-06-19
JP2025509728A (ja) 2025-04-11
EP4493219A1 (en) 2025-01-22
CN119212725A (zh) 2024-12-27
US20250108106A1 (en) 2025-04-03
WO2023178038A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
CN119233828A (zh) 纳米胶囊化药物组合物及其用途
Jain et al. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B
CN103429267B (zh) 疏水分子诱导的支化聚合物集合体及其用途
US11957785B2 (en) Film dosage form with extended release mucoadhesive particles
Guggi et al. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin
EP0974365B1 (fr) Utilisation d'un polymère de type acrylique en tant qu'agent de désagrégation, procédé pour faire des comprimés et comprimés en résultant
Jain et al. PEG–PLA–PEG block copolymeric nanoparticles for oral immunization against hepatitis B
Simón-Vázquez et al. Polymeric nanostructure vaccines: applications and challenges
Biswas et al. Understanding mucosal physiology and rationale of formulation design for improved mucosal immunity
JP2026015426A (ja) ワクチンアジュバントとしてのポリマーナノ粒子
US12544342B2 (en) Pharmaceutical composition containing taxane nanoaggregates and use thereof
Rasool et al. Advances in vaccine delivery strategies to promote effective immunization
US20260078219A1 (en) Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof
Jacob et al. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics 2021, 13, 1206
Kharwade et al. Role of nanocarriers for the effective delivery of anti-HIV drugs
KR102092258B1 (ko) 광감각제가 접합된 고분자를 유효성분으로 포함하는 면역증강제, 바이러스 감염 또는 암 예방 또는 치료용 백신 조성물
Andrianov Delivery of protein therapeutics and vaccines using their multivalent complexes with synthetic polyelectrolytes
US20260007737A1 (en) Lipid polysaccharide amino acid nanoparticles and use thereof
JP6419725B2 (ja) タキサンを含有するナノ粒子およびその使用
WO2025166213A1 (en) Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
Ulery Molecular design of nanoparticle-based delivery vehicles for pneumonic plague
WO2014120804A1 (en) Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
Lu EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT
ECSP993175A (es) Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination